Carbapenem-based Antibiotics Market to Register Strong Growth, on Back of Increasing Incidence of Hospital Acquired Pneumonia and Bacterial Infections
Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics.
As per the Center for Disease Control (CDC), people admitted to hospital settings due to various reasons such as immunosuppressive treatment and inappropriately followed infection control protocol, suffer from hospital-acquired pneumonia (HAP). Along with HAP, incidence of various bacterial diseases is increasing rapidly, which in turn is expected to drive the growth of the carbapenem-based antibiotics market.
Surgery-Associated Bacterial Infection to Boost Demand for Carbapenem-Based Antibiotics
Some forms of chronic diseases often require open surgery as a treatment protocol. Before performing open surgery, carbapenem-based antibiotics are often administered as the prophylactic measure for the prevention of surgery-related bacterial infections.
The World Health Organization also emphasizes on infection control protocol i.e. prophylactic administration of the carbapenem-based antibiotics that can limit or eliminate the chances of surgery-associated bacterial infection. As per WHO, 30% of global disease burden is accruing to surgery related diseases pointing towards a heightened demand for prophylactic, carbapenem-based antibiotics.
Carbapenem-based Antibiotics Market Gains Traction, with Generic Alternatives to Ertapenem to be Lucrative Revenue Pockets
Ertapenem is one of the most widely used carbapenem-based antibiotics and its patent expired in November 2017. Various regional as well as global pharmaceutical companies are assessing feasibility for possible re- launch of generic version of ertapenem in various regions.
For instance, in June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection. Invanz is Merck Sharp and Dohme Corp.’s joint carbapenem-based antibiotic product for the treatment of various bacterial infections. The launch of various generic version of carbapenem-based antibiotics such as ertapenem in regions such as North America and Europe is expected to offer substantial revenue generation opportunities.
Lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to enhance geographical footprint in lower- and middle-income countries. Increasing supply-chain operations in regions such as North America, East Asia and Europe will further give impetus to high revenue generating carbapenem-based antibiotics markets.
Competitive Landscape
- Pfizer Inc.
- Merck Co. & Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
are top players operating in the carbapenem-based antibiotics market. The top three players contributed more than 92% revenue share in the carbapenem-based antibiotics market in 2018.
Key players are prominently focusing on increasing their carbapenem-based antibiotics availability in different countries for the treatment of a large patient pool with bacterial infections.
